INDP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Indaptus Therapeutics Inc (INDP) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown significant recent price increases, the technical indicators suggest it is overbought, and the financial performance is weak with no revenue growth and worsening net income. Additionally, there are no significant positive catalysts or trading signals to justify immediate investment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 89.418, signaling an overbought condition, which suggests the stock may be overvalued in the short term. Moving averages are converging, and the stock is trading near resistance levels (R2: 3.226).
The stock has shown a significant price increase recently, with a 12.18% gain in regular market trading and additional gains in pre-market and post-market sessions. The MACD indicates bullish momentum.
The RSI indicates the stock is overbought, suggesting a potential pullback. Financial performance is weak, with no revenue growth, a significant net income loss, and a sharp decline in EPS. There are no recent news catalysts or significant insider/hedge fund activity.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$2,975,117 (-3.06% YoY), and a sharp decline in EPS (-67.04% YoY). Gross margin remains at 0%.
No analyst rating or price target changes available.
